Literature DB >> 16972063

Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis.

Jarogniew J Luszczki1, Stanislaw J Czuczwar.   

Abstract

The anticonvulsant effects produced by stiripentol (STP), carbamazepine (CBZ), and their combination in the maximal electroshock (MES)-induced seizures in mice were investigated using three-dimensional (3D) isobolographic analysis. With 3D isobolography, the combinations of both drugs at the fixed-ratios of 1:3, 1:1, and 3:1 for 16%, 50% and 84% antiseizure effects, respectively, were examined in order to evaluate the preclinical characteristics of the interactions between STP and CBZ. Additionally, to characterize precisely the types of interactions observed in the MES test, free plasma and total brain CBZ concentrations were estimated for all fixed-ratios tested. The 3D isobolographic analysis showed that STP and CBZ combined at the fixed-ratio of 1:3 produced supra-additive (synergistic) interactions in the MES test for the anticonvulsant effects ranging between 16% and 84%. In contrast, the combination of STP with CBZ at the fixed-ratio of 3:1 exerted sub-additive (antagonistic) interactions in 3D isobolography for all antiseizure effects examined in the MES test. Only the combination of STP and CBZ at the fixed-ratio of 1:1 was additive for the investigated effects (16%, 50% and 84%) in 3D isobolography. Pharmacokinetic evaluation of CBZ concentrations revealed that STP increased both free plasma and total brain CBZ concentrations for all fixed-ratio combinations tested (1:3, 1:1 and 3:1). In conclusion, the 3D isobolographic findings suggest that the combination of STP with CBZ exerted biphasic characteristics of interactions in the MES test, despite the pharmacokinetic increase in CBZ content in plasma and brains of experimental animals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972063     DOI: 10.1007/s00210-006-0100-3

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  40 in total

1.  Response surface model for anesthetic drug interactions.

Authors:  C F Minto; T W Schnider; T G Short; K M Gregg; A Gentilini; S L Shafer
Journal:  Anesthesiology       Date:  2000-06       Impact factor: 7.892

2.  Assessing the (a)symmetry of concentration-effect curves: empirical versus mechanistic models.

Authors:  Jesús Giraldo; Nuria M Vivas; Elisabet Vila; Albert Badia
Journal:  Pharmacol Ther       Date:  2002-07       Impact factor: 12.310

3.  The interaction index: a measure of drug synergism.

Authors:  Ronald J Tallarida
Journal:  Pain       Date:  2002-07       Impact factor: 6.961

4.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

5.  Zero interaction response surfaces, interaction functions and difference response surfaces for combinations of biologically active agents.

Authors:  J Sühnel
Journal:  Arzneimittelforschung       Date:  1992-10

6.  Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats.

Authors:  Miren Cadart; Sandrine Marchand; Claudine Pariat; Serge Bouquet; William Couet
Journal:  Pharm Res       Date:  2002-02       Impact factor: 4.200

7.  Stiripentol: efficacy and tolerability in children with epilepsy.

Authors:  J Perez; C Chiron; C Musial; E Rey; H Blehaut; P d'Athis; J Vincent; O Dulac
Journal:  Epilepsia       Date:  1999-11       Impact factor: 5.864

8.  Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Neville Ratnaraj; Philip N Patsalos; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-08       Impact factor: 3.000

9.  Michaelis-Menten kinetics of stiripentol in normal humans.

Authors:  R H Levy; P Loiseau; M Guyot; H M Blehaut; J Tor; T A Moreland
Journal:  Epilepsia       Date:  1984-08       Impact factor: 5.864

10.  Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

View more
  12 in total

1.  Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.

Authors:  Ewelina Gumbarewicz; Jarogniew J Luszczki; Anna Wawruszak; Magdalena Dmoszynska-Graniczka; Aneta J Grabarska; Agata M Jarząb; Krzysztof Polberg; Andrzej Stepulak
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application.

Authors:  Jarogniew J Luszczki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-01       Impact factor: 3.000

3.  Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.

Authors:  Paweł Marzęda; Paula Wróblewska-Łuczka; Małgorzata Drozd; Magdalena Florek-Łuszczki; Katarzyna Załuska-Ogryzek; Jarogniew J Łuszczki
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

4.  Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves.

Authors:  Jarogniew J Luszczki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-20       Impact factor: 3.000

5.  Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Jim Z Wu; Grzegorz Raszewski; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-05       Impact factor: 3.000

6.  Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells.

Authors:  Aneta Grabarska; Jarogniew J Łuszczki; Ewa Nowosadzka; Ewelina Gumbarewicz; Witold Jeleniewicz; Magdalena Dmoszyńska-Graniczka; Krystyna Kowalczuk; Krzysztof Kupisz; Krzysztof Polberg; Andrzej Stepulak
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

7.  Polygonogram and isobolographic analysis of interactions between various novel antiepileptic drugs in the 6-Hz corneal stimulation-induced seizure model in mice.

Authors:  Jarogniew J Luszczki; Anna Panasiuk; Mirosław Zagaja; Sławomir Karwan; Hubert Bojar; Zbigniew Plewa; Magdalena Florek-Łuszczki
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.240

8.  Synergistic or Additive Pharmacological Interactions between Magnoflorine and Cisplatin in Human Cancer Cells of Different Histological Origin.

Authors:  Estera Okon; Jarogniew J Luszczki; Wirginia Kukula-Koch; Marta Halasa; Agata Jarzab; Daariimaa Khurelbat; Andrzej Stepulak; Anna Wawruszak
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

9.  Interactions among Lacosamide and Second-Generation Antiepileptic Drugs in the Tonic-Clonic Seizure Model in Mice.

Authors:  Katarzyna Załuska-Ogryzek; Paweł Marzęda; Paula Wróblewska-Łuczka; Magdalena Florek-Łuszczki; Zbigniew Plewa; Hubert Bojar; Dorota Zolkowska; Jarogniew J Łuszczki
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

10.  Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.

Authors:  Anna Wawruszak; Jarogniew J Luszczki; Aneta Grabarska; Ewelina Gumbarewicz; Magdalena Dmoszynska-Graniczka; Krzysztof Polberg; Andrzej Stepulak
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.